샘플 요청 목록

 카트 문의
시장보고서
상품코드
1866720

세계의 탁시폴린 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)

Taxifolin - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
발행일: | 리서치사: QYResearch | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 탁시폴린 시장 규모는 2024년에 2,600만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 4.1%로 성장하여 2031년까지 3,818만 달러로 확대될 것으로 예측됩니다.

본 보고서는 탁시폴린의 국경 간 산업 발자국, 자본 배분 패턴, 지역 경제의 상호 의존성, 공급망 재구축에 대한 최근 관세 조정 및 국제적인 전략적 대응 조치에 대한 종합적인 평가를 제공합니다.

2024년 세계 탁시폴린 판매량은 20,000kg에 달했으며, 평균 판매가격은 약 1,300달러/kg였습니다. 탁시폴린(일명 디하이드로케르세틴)은 시베리아 낙엽송, 엉겅퀴, 양파 등 다양한 식물에 함유되어 있는 천연 플라보노이드입니다. 강력한 항산화, 항염증, 항노화 작용으로 유명하며, 영양 보충제 및 스킨케어 제품에 많이 사용되는 성분입니다. 탁시폴린은 구조적으로 잘 알려진 플라보노이드인 케르세틴과 유사하지만, 더 높은 수용성과 안정성을 자랑하며 생체 이용률과 치료 효과를 높입니다. 연구에 따르면, 심혈관 건강 유지, 면역 기능 향상, 세포의 산화 스트레스로부터의 보호에 기여할 수 있다고 합니다.

세계 주요 탁시폴린 제조업체로는 아메티스, 로바이오스, JW헬스프로덕츠 등이 있습니다. 상위 3개사가 약 96%의 점유율을 차지하고 있습니다. 아시아태평양이 가장 큰 시장으로 약 34%의 점유율을 차지하고 있으며, 유럽과 아메리카 지역이 그 뒤를 잇고 있습니다. 제품별로는 순도 92% 미만의 제품이 가장 큰 부문이며, 점유율은 약 72%를 기록했습니다. 용도별로는 헬스케어 분야가 가장 큰 용도이며, 약 40%의 점유율을 차지하고 있습니다.

탁신 시장의 주요 성장 요인은 다음과 같습니다:

I. 제약 분야 수요 급증 및 임상 적용 범위 확대

1. 항암제의 핵심 성분 및 적응증 확대

뛰어난 항암 효과 : 천연 항암 활성 성분인 탁신은 유방암, 난소암 등 고형암 치료에 높은 효과를 발휘합니다. 2023년 세계 시장 규모는 9억 2,000만 달러에 달할 것으로 예상되며, 중국이 28%를 차지할 것으로 전망됩니다. 표적 지향적 약물 개발이 가속화되고 있으며, 폐암, 위암 등의 적응증에 대한 임상시험 건수는 2020년 대비 3.2배 증가했습니다. 이들 약품은 2025년까지 8억-10억 위안의 시장 점유율 확대에 기여할 것으로 예상됩니다.

정책 지원 및 의료보험 적용 : 국가약품감독관리국의 '항암제 우선 심사 기술 가이드라인'에 따라 탁산계 제제의 심사가 신속히 진행되어 승인 주기가 180일로 단축되었습니다. 의료보험 적용 범위의 동적 조정으로 파클리탁셀 계열 약품의 보험 적용률이 65%에서 82%로 높아져 환자의 연간 치료비가 32,000-48,000위안으로 줄어들어 약품의 접근성이 크게 향상되었습니다. 2. 제제 기술 혁신 및 연구개발 투자

신규 약물전달 시스템 : 리포솜 전달 시스템, 나노결정 기술 등 새로운 약물전달 방법을 통해 생체 이용률이 40-60% 향상되었고, 약물 독성 및 부작용이 약 30% 정도 감소되었습니다.

II. 건강식품-화장품 시장의 소비 고도화

1. 천연 항산화제에 대한 수요 급증

건강 인식의 증가 : 만성질환 및 산화 스트레스 관련 질환에 대한 전 세계적인 인식이 높아지면서 천연 항산화제 및 건강보조식품에 대한 소비자 수요가 증가하고 있습니다.

기능성 식품 및 농업 분야 적용

2. 화장품 효과의 비약적 향상

항노화 및 미백 효과 : 탁시폴린을 0.5% 농도로 사용했을 때 8주 동안 피부 탄력을 27% 향상시키고 주름의 깊이를 33% 감소시키는 것으로 확인되었습니다. 또한 비경쟁적으로 티로시나제 활성을 억제하여 알부틴을 능가하는 효과를 발휘합니다.

고급 브랜드에 적용 : 프로야 등 브랜드가 핵심 성분으로 채택하여 관련 제품의 가격 프리미엄을 300-500%까지 끌어올렸습니다. 의료용 드레싱은 레이저 수술 후 수복에 사용되어 홍반과 색소 침착을 감소시킵니다.

III. 기술 혁신과 비용 최적화를 통한 산업화 추진

1. 추출 기술 혁신과 환경 규제 대응

초임계 CO2 추출 기술 : 보급률은 2020년 18%에서 2025년 43%로 상승하고, 잔류 용매 수준은 0.02ppm 이하로 감소합니다. 유럽과 미국의 cGMP 기준을 충족하는 기업 수는 300% 증가할 것으로 예상됩니다.

합성생물학 및 세포배양 : 화학합성(반합성, 완전합성)은 저비용과 높은 수율로 인해 주류 제조법으로 자리 잡았습니다. 상장 기업의 50톤 바이오리액터 생산 라인에서 추출 효율이 12배 향상되고, 단일 사이클의 생산 비용이 58% 절감되었습니다.

2. 원자재 공급 및 지속가능한 개발

인공 재배 기지 확대 : 천연 이치 자원은 한정되어 있어 인공 재배 면적은 연평균 24%씩 확대되어 2023년에는 12만 8천 무에 달합니다. 윈난성과 쓰촨성이 국내 원료 공급량의 65%를 차지할 것으로 예상됩니다. '1만 무(약 667헥타르) 규모의 Yew GAP 기지' 프로젝트가 착공되어 2027년까지 원료 자급률 70%를 달성할 계획입니다. 환경 정책 추진 : 초임계 CO2 추출 기술은 용매 오염을 줄이고, 지속가능한 발전의 요구에 부합하며, 업계의 녹색 제조로의 전환을 촉진합니다.

탁시폴린 시장은 의약품 분야의 폭발적인 수요, 건강보조식품 및 화장품 소비 증가, 기술 발전 및 비용 최적화로 인해 빠르게 성장하고 있습니다.

이 보고서는 탁시폴린 세계 시장에 대해 총 판매량, 매출액, 가격, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목표로 합니다.

이 보고서는 2024년을 기준 연도, 2020년에서 2031년까지의 과거 데이터와 예측 데이터를 포함하여 판매량(킬로그램)과 매출액(백만 달러)으로 탁시폴린 시장 규모와 추정 및 예측을 제시했습니다. 정량적, 정성적 분석을 통해 독자들이 탁시폴린 관련 사업 전략 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 자사 포지셔닝 분석, 정보에 입각한 비즈니스 의사결정을 내리는데 도움을 드리고자 합니다.

시장 세분화

기업별

  • Ametis JSC
  • Jilin Jianwei Natural Biotechnology
  • Kalenika Group
  • ROBIOS
  • Xi'an Sost Biotech Co.,Ltd
  • Focusherb
  • Hoycome
  • Herbchem Biotech

유형별 부문

  • 92% 미만
  • 92%-98%
  • 98% 이상

용도별 부문

  • 식품 및 음료
  • 헬스케어
  • 화장품
  • 농업
  • 기타

지역별

  • 북미
    • 미국
    • 캐나다
  • 아시아태평양
    • 중국
    • 일본
    • 한국
    • 동남아시아
    • 인도
    • 호주
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 네덜란드
    • 북유럽 국가
    • 기타 유럽
  • 라틴아메리카
    • 멕시코
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • 튀르키예
    • 사우디아라비아
    • 아랍에미리트
    • 기타 중동 및 아프리카
KSM

The global market for Taxifolin was estimated to be worth US$ 26.00 million in 2024 and is forecast to a readjusted size of US$ 38.18 million by 2031 with a CAGR of 4.1% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Taxifolin cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

In 2024, global taxifolin sales will reach 20,000 kg, with an average selling price of approximately US$1,300/kg.Taxifolin, also known as dihydroquercetin, is a natural flavonoid found in plants as diverse as Siberian larch, milk thistle, and onion. It is known for its potent antioxidant, anti-inflammatory, and anti-aging properties, making it a popular ingredient in dietary supplements and skincare products. Taxifolin is structurally similar to the well-known flavonoid quercetin, but boasts greater water solubility and stability, enhancing its bioavailability and therapeutic potential. Research suggests it may support cardiovascular health, improve immune function, and protect cells from oxidative stress.

Global key taxifolin players include Ametis, ROBIOS and JW Health Products etc. The top 3 companies hold a share about 96%. Asia-Pacific is the largest market with a share about 34%, followed by Europe and America. In terms of product, the product whose purity is below 92% is the largest segment with a share about 72%. And in terms of applications, the largest application is healthcare with a share about 40%.

The main drivers of the taxusin market include the following:

I. Explosive demand in the pharmaceutical sector and expansion of clinical applications

1. Expansion of core ingredients and indications for anticancer drugs

Significant anticancer effects: Taxusin, a natural anticancer active ingredient, is highly effective in treating solid tumors such as breast and ovarian cancer. The global market size is expected to reach US$920 million in 2023, with China accounting for 28%. Targeted drug development is accelerating, with the number of clinical trials for indications such as lung and gastric cancer increasing 3.2-fold compared to 2020. It is expected that these drugs will contribute an incremental market share of 800 million to 1 billion yuan in 2025.

Policy support and medical insurance coverage: The National Medical Products Administration's "Technical Guidelines for Priority Review of Anticancer Drugs" has fast-tracked taxusin compound preparations, shortening the approval cycle to 180 working days. Dynamic adjustments to the medical insurance catalog have increased the reimbursement rate for paclitaxel-based drugs from 65% to 82%, reducing annual treatment costs for patients to 32,000 to 48,000 yuan, significantly improving drug accessibility. 2. Formulation Technology Innovation and R&D Investment

New Drug Delivery Systems: New drug delivery methods such as liposome delivery systems and nanocrystal technology have increased bioavailability by 40%-60% and reduced drug toxicity and side effects by approximately 30%.

II. Consumption Upgrade in the Health Products and Cosmetics Market

1. Surge in Demand for Natural Antioxidants

Rising Health Awareness: Global awareness of chronic diseases and oxidative stress-related conditions is increasing, driving consumer demand for natural antioxidants and health supplements.

Functional Foods and Agricultural Applications

2. Efficacy Breakthroughs in Cosmetics

Anti-Aging and Whitening Effects: Taxifolin at a concentration of 0.5% can increase skin elasticity by 27% and reduce wrinkle depth by 33% for eight weeks. It also non-competitively inhibits tyrosinase activity, surpassing arbutin in effectiveness.

High-End Brand Applications: Brands such as Proya use it as a core ingredient, driving price premiums of 300%-500% for related products. Medical dressings are used for post-laser surgery repair, reducing erythema and hyperpigmentation.

III. Technological Advances and Cost Optimization Drive Industrialization

1. Extraction Technology Breakthroughs and Environmental Compliance

Supercritical CO2 Extraction Technology: The penetration rate will increase from 18% in 2020 to 43% in 2025, with residual solvent levels reduced to below 0.02 ppm. The number of companies meeting European and American cGMP standards will increase by 300%.

Synthetic Biology and Cell Culture: Chemical synthesis (semi-synthesis and total synthesis) has become the mainstream preparation method due to its low cost and high yield. A listed company's 50-ton bioreactor production line has increased extraction efficiency by 12-fold and reduced single-cycle production costs by 58%.

2. Raw Material Supply and Sustainable Development

Expansion of Artificial Planting Bases: Wild yew resources are limited, and the area of artificial planting is expanding at an average annual rate of 24%, reaching 128,000 mu in 2023. Yunnan and Sichuan will together contribute 65% of the national raw material supply. Construction of the "10,000 Mu Yew GAP Base" project has commenced, with an expected raw material self-sufficiency rate of 70% by 2027. Driven by environmental policies: Supercritical CO2 extraction technology reduces solvent pollution, aligns with sustainable development requirements, and promotes the industry's transition to green manufacturing.

The taxifolin market is experiencing rapid growth driven by explosive demand in the pharmaceutical sector, rising consumption of health supplements and cosmetics, and technological advancements and cost optimization.

This report aims to provide a comprehensive presentation of the global market for Taxifolin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Taxifolin by region & country, by Type, and by Application.

The Taxifolin market size, estimations, and forecasts are provided in terms of sales volume (KG) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Taxifolin.

Market Segmentation

By Company

  • Ametis JSC
  • Jilin Jianwei Natural Biotechnology
  • Kalenika Group
  • ROBIOS
  • Xi'an Sost Biotech Co.,Ltd
  • Focusherb
  • Hoycome
  • Herbchem Biotech

Segment by Type

  • Below 92%
  • 92%-98%
  • Above 98%

Segment by Application

  • Food and Beverages
  • Healthcare
  • Cosmetics
  • Agriculture
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Taxifolin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Taxifolin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Taxifolin in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Taxifolin Product Introduction
  • 1.2 Global Taxifolin Market Size Forecast
    • 1.2.1 Global Taxifolin Sales Value (2020-2031)
    • 1.2.2 Global Taxifolin Sales Volume (2020-2031)
    • 1.2.3 Global Taxifolin Sales Price (2020-2031)
  • 1.3 Taxifolin Market Trends & Drivers
    • 1.3.1 Taxifolin Industry Trends
    • 1.3.2 Taxifolin Market Drivers & Opportunity
    • 1.3.3 Taxifolin Market Challenges
    • 1.3.4 Taxifolin Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Taxifolin Players Revenue Ranking (2024)
  • 2.2 Global Taxifolin Revenue by Company (2020-2025)
  • 2.3 Global Taxifolin Players Sales Volume Ranking (2024)
  • 2.4 Global Taxifolin Sales Volume by Company Players (2020-2025)
  • 2.5 Global Taxifolin Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Taxifolin Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Taxifolin Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Taxifolin
  • 2.9 Taxifolin Market Competitive Analysis
    • 2.9.1 Taxifolin Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Taxifolin Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Taxifolin as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Below 92%
    • 3.1.2 92%-98%
    • 3.1.3 Above 98%
  • 3.2 Global Taxifolin Sales Value by Type
    • 3.2.1 Global Taxifolin Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Taxifolin Sales Value, by Type (2020-2031)
    • 3.2.3 Global Taxifolin Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Taxifolin Sales Volume by Type
    • 3.3.1 Global Taxifolin Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Taxifolin Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Taxifolin Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Taxifolin Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Food and Beverages
    • 4.1.2 Healthcare
    • 4.1.3 Cosmetics
    • 4.1.4 Agriculture
    • 4.1.5 Others
  • 4.2 Global Taxifolin Sales Value by Application
    • 4.2.1 Global Taxifolin Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Taxifolin Sales Value, by Application (2020-2031)
    • 4.2.3 Global Taxifolin Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Taxifolin Sales Volume by Application
    • 4.3.1 Global Taxifolin Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Taxifolin Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Taxifolin Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Taxifolin Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Taxifolin Sales Value by Region
    • 5.1.1 Global Taxifolin Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Taxifolin Sales Value by Region (2020-2025)
    • 5.1.3 Global Taxifolin Sales Value by Region (2026-2031)
    • 5.1.4 Global Taxifolin Sales Value by Region (%), (2020-2031)
  • 5.2 Global Taxifolin Sales Volume by Region
    • 5.2.1 Global Taxifolin Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Taxifolin Sales Volume by Region (2020-2025)
    • 5.2.3 Global Taxifolin Sales Volume by Region (2026-2031)
    • 5.2.4 Global Taxifolin Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Taxifolin Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Taxifolin Sales Value, 2020-2031
    • 5.4.2 North America Taxifolin Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Taxifolin Sales Value, 2020-2031
    • 5.5.2 Europe Taxifolin Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Taxifolin Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Taxifolin Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Taxifolin Sales Value, 2020-2031
    • 5.7.2 South America Taxifolin Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Taxifolin Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Taxifolin Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Taxifolin Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Taxifolin Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Taxifolin Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Taxifolin Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Taxifolin Sales Value, 2020-2031
    • 6.3.2 United States Taxifolin Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Taxifolin Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Taxifolin Sales Value, 2020-2031
    • 6.4.2 Europe Taxifolin Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Taxifolin Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Taxifolin Sales Value, 2020-2031
    • 6.5.2 China Taxifolin Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Taxifolin Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Taxifolin Sales Value, 2020-2031
    • 6.6.2 Japan Taxifolin Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Taxifolin Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Taxifolin Sales Value, 2020-2031
    • 6.7.2 South Korea Taxifolin Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Taxifolin Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Taxifolin Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Taxifolin Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Taxifolin Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Taxifolin Sales Value, 2020-2031
    • 6.9.2 India Taxifolin Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Taxifolin Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Ametis JSC
    • 7.1.1 Ametis JSC Company Information
    • 7.1.2 Ametis JSC Introduction and Business Overview
    • 7.1.3 Ametis JSC Taxifolin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Ametis JSC Taxifolin Product Offerings
    • 7.1.5 Ametis JSC Recent Development
  • 7.2 Jilin Jianwei Natural Biotechnology
    • 7.2.1 Jilin Jianwei Natural Biotechnology Company Information
    • 7.2.2 Jilin Jianwei Natural Biotechnology Introduction and Business Overview
    • 7.2.3 Jilin Jianwei Natural Biotechnology Taxifolin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Jilin Jianwei Natural Biotechnology Taxifolin Product Offerings
    • 7.2.5 Jilin Jianwei Natural Biotechnology Recent Development
  • 7.3 Kalenika Group
    • 7.3.1 Kalenika Group Company Information
    • 7.3.2 Kalenika Group Introduction and Business Overview
    • 7.3.3 Kalenika Group Taxifolin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Kalenika Group Taxifolin Product Offerings
    • 7.3.5 Kalenika Group Recent Development
  • 7.4 ROBIOS
    • 7.4.1 ROBIOS Company Information
    • 7.4.2 ROBIOS Introduction and Business Overview
    • 7.4.3 ROBIOS Taxifolin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 ROBIOS Taxifolin Product Offerings
    • 7.4.5 ROBIOS Recent Development
  • 7.5 Xi'an Sost Biotech Co.,Ltd
    • 7.5.1 Xi'an Sost Biotech Co.,Ltd Company Information
    • 7.5.2 Xi'an Sost Biotech Co.,Ltd Introduction and Business Overview
    • 7.5.3 Xi'an Sost Biotech Co.,Ltd Taxifolin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Xi'an Sost Biotech Co.,Ltd Taxifolin Product Offerings
    • 7.5.5 Xi'an Sost Biotech Co.,Ltd Recent Development
  • 7.6 Focusherb
    • 7.6.1 Focusherb Company Information
    • 7.6.2 Focusherb Introduction and Business Overview
    • 7.6.3 Focusherb Taxifolin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Focusherb Taxifolin Product Offerings
    • 7.6.5 Focusherb Recent Development
  • 7.7 Hoycome
    • 7.7.1 Hoycome Company Information
    • 7.7.2 Hoycome Introduction and Business Overview
    • 7.7.3 Hoycome Taxifolin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Hoycome Taxifolin Product Offerings
    • 7.7.5 Hoycome Recent Development
  • 7.8 Herbchem Biotech
    • 7.8.1 Herbchem Biotech Company Information
    • 7.8.2 Herbchem Biotech Introduction and Business Overview
    • 7.8.3 Herbchem Biotech Taxifolin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Herbchem Biotech Taxifolin Product Offerings
    • 7.8.5 Herbchem Biotech Recent Development

8 Industry Chain Analysis

  • 8.1 Taxifolin Industrial Chain
  • 8.2 Taxifolin Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Taxifolin Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Taxifolin Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제